Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome

Nephrology Dialysis Transplantation

Volumn 29, Issue 3, 2014, Pages 538-543

  Liu, Shuman ^a   Vaziri, Nosratola D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Lipid disorders; Liver X receptor; Proteinuria

Indexed keywords

INDUCIBLE DEGRADER OF THE LOW DENSITY LIPOPROTEIN RECEPTOR; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PUROMYCIN; SERINE PROTEINASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYLIP PROTEIN, RAT; ORPHAN NUCLEAR RECEPTOR; PCSK9 PROTEIN, RAT; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HYPERCHOLESTEROLEMIA; LIPOPROTEIN DEFICIENCY; LIVER; LOW DENSITY LIPOPROTEIN RECEPTOR DEFICIENCY; MALE; NEPHROTIC SYNDROME; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; ANIMAL; BLOOD; ENZYMOLOGY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE EXPRESSION; METABOLISM; PHYSIOLOGY; PROTEIN TRANSPORT; SPRAGUE DAWLEY RAT;

ANIMALS; CHOLESTEROL, LDL; GENE EXPRESSION; HYPERLIPOPROTEINEMIA TYPE II; LIVER; MALE; NEPHROTIC SYNDROME; ORPHAN NUCLEAR RECEPTORS; PROTEIN TRANSPORT; RATS, SPRAGUE-DAWLEY; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; UBIQUITIN-PROTEIN LIGASES;

EID: 84895749296     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft439     Document Type: Article

References (40)

1. Vaziri ND. Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int 2003; 63: 1964-1976
2. Joven J, Villabona C, Vilella E et al. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 1990; 323: 579-584
3. Kaysen GA, de Sain-van der Velden MG. New insights into lipid metabolism in the nephrotic syndrome. Kidney Int 1999; 71: S18-S21
4. Warwick GL, Packard CJ, Demant T et al. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria. Kidney Int 1991; 40: 129-138
5. Warwick GL, Caslake MJ, Boulton-Jones JMet al. Low-density lipoprotein metabolism in the nephrotic syndrome. Metabolism 1990; 39: 187-192
6. Vaziri ND, Liang K. Downregulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 1996; 50: 887-893
7. Vaziri ND, Sato T, Liang K. Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int 2003; 63: 1756-1763
8. Vaziri ND, Liang K. Acyl-CoA cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, LCAT, SRB-1 and LDL receptor deficiencies in nephrotic syndrome. Circulation 2004; 110: 419-425
9. Kim CH, Kim HJ, Mitsuhashi M et al. Hepatic tissue sterol regulatory element binding protein 2 and low-density lipoprotein receptor in nephrotic syndrome. Metabolism 2007; 56: 1377-1382
10. Zelcer N, Hong C, Boyadjian R et al. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009; 325: 100-104
11. Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA 2004; 101: 7100-7105
12. Lagace TA, Curtis DE, Garuti R et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and livers of parabiotic mice. J Clin Invest 2006; 116: 2995-3005
13. Li J, Tumanut C, Gavigan JA et al. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem J 2007; 406: 203-207
14. McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem 2007; 282: 20799-20803
15. Cohen JC, Boerwinkle E, Mosley TH, Jr et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-1272
16. Zhang L, Reue K, Fong LG et al. Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis. Arterioscler Thromb Vasc Biol 2012; 32: 2541-2546
17. Kim CH, Kim HJ, Mitsuhashi M et al. Hepatic tissue sterol regulatory element-binding protein-2 (SREBP-2) and LDL receptor in nephrotic syndrome. Metabolism 2007; 56: 1377-1382
18. Vaziri ND, Liang KH. Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 1995; 48: 1979-1985
19. Alborn WE, Cao G, Careskey HE et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007; 53: 1814-1819
20. Lambert G, Ancellin N, Charlton F et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008; 54: 1038-1045
21. Chan DC, Lambert G, Barrett PH et al. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism? Clin Chem 2009; 55: 2049-2052
22. Huijgen R, Boekholdt SM, Arsenault BJ et al. Plasma PCSK9 levels and clinical outcomes in the treating to new targets trial: a nested case-control study. J Am Coll Cardiol 2012; 59: 1778-1784
23. Jeong HJ, Lee HS, Kim KS et al. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res 2008; 49: 399-409
24. Dong B, Wu M, Li H et al. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDLcholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res 2010; 51: 1486-1495
25. Careskey HE, Davis RA, Alborn WE et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008; 49: 394-398
26. Mayne J, Dewpura T, Raymond A et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 2008; 7: 22
27. Rashid S, Curtis DE, Garuti R et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA 2005; 102: 5374-5379
28. Vaziri ND, Liang KH. Upregulation of Acyl-Coenzyme A: cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int 2002; 61: 1769-1775
29. Kwon HJ, Lagace TA, McNutt MC et al. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA 2008; 105: 1820-1825
30. Zhang DW, Lagace TA, Garuti R et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007; 282: 18602-18612
31. Scotti E, Hong C, Yoshinaga Y et al. Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists. Mol Cell Biol 2011; 31: 1885-1893
32. Hong C, Duit S, Jalonen P et al. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2. J Biol Chem 2010; 285: 19720-19726
33. Sato T, Liang K, Vaziri ND. Down-regulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis. Kidney Int 2002; 61: 157-162
34. Liang K, Vaziri ND. Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Int 1997; 51: 1761-1765
35. Wang L, Shearer GC, Budamagunta MS et al. Proteinuria decreases tissue lipoprotein receptor levels resulting in altered lipoprotein structure and increasing lipid levels. Kidney Int 2012; 82: 990-999
36. Vega GL, Grundy SM. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism. Kidney Int 1988; 33: 1160-1168
37. Aguilar-Salinas CA, Barrett PH, Kelber J et al. Physiologic mechanisms of action of lovastatin in nephrotic syndrome. J Lipid Res 1995; 36: 188-199
38. de Sain-van der Velden MG, Kaysen GA, Barrett HA et al. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. Kidney Int 1998; 4: 994-1001
39. Persson L, Cao G, Ståhle L et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol 2010; 30: 2666-2672
40. Browning JD, Horton JD. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res 2010; 51: 3359-3363